Angelika M. Starzer

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Immune remodelling and molecular profiling of progressive brain metastases following cranial radiotherapy.

Immune remodelling and molecular profiling of progressive brain metastases following cranial radiotherapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 19, 2026

Digital health technology in oncology: results from a survey by the ESMO Young Oncologists Committee and medical student alumni.

Digital health technology in oncology: results from a survey by the ESMO Young Oncologists Committee and medical student alumni.

Journal: ESMO real world data and digital oncology

Published: April 09, 2026

Gene-Specific Outcomes After Central Nervous System Metastases in Germline BRCA1- and BRCA2-Associated Breast Cancer.

Gene-Specific Outcomes After Central Nervous System Metastases in Germline BRCA1- and BRCA2-Associated Breast Cancer.

Journal: Cancers

Published: March 12, 2026

Severe Immune-Related Neurological Adverse Events Associated With Immune Checkpoint Inhibitor Treatment: A Retrospective Single-Center Study.

Severe Immune-Related Neurological Adverse Events Associated With Immune Checkpoint Inhibitor Treatment: A Retrospective Single-Center Study.

Journal: European journal of neurology

Published: March 11, 2026

Early radiological response pattern predicts long-term response in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors.

Early radiological response pattern predicts long-term response in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors.

Journal: Cancer imaging : the official publication of the International Cancer Imaging Society

Published: February 19, 2026

Inflammatory biomarkers refine progression risk stratification in NSCLC patients with stable disease.

Inflammatory biomarkers refine progression risk stratification in NSCLC patients with stable disease.

Journal: Translational oncology

Published: January 15, 2026

Peripheral blood DNA methylation profile and immune checkpoint inhibitor response in cancer patients.

Peripheral blood DNA methylation profile and immune checkpoint inhibitor response in cancer patients.

Journal: ESMO open

Published: December 15, 2025

Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from Austria.

Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from Austria.

Journal: ESMO open

Published: November 21, 2025

Concomitant radiation therapy and trastuzumab deruxtecan in metastatic breast cancer: feasibility, safety, and outcomes from a real-life multicentre international cohort.

Concomitant radiation therapy and trastuzumab deruxtecan in metastatic breast cancer: feasibility, safety, and outcomes from a real-life multicentre international cohort.

Journal: Breast (Edinburgh, Scotland)

Published: November 07, 2025

Predictive potential of patient-specific immunological characteristics in solid cancers: circulating monocytes, myeloid-derived suppressor cells, T cells, and the T-cell receptor repertoire.

Predictive potential of patient-specific immunological characteristics in solid cancers: circulating monocytes, myeloid-derived suppressor cells, T cells, and the T-cell receptor repertoire.

Journal: ESMO open

Published: September 22, 2025

Clinical impact of single-gene vs. panel sequencing in advanced HR + /HER2- breast cancer: insights and implications.

Clinical impact of single-gene vs. panel sequencing in advanced HR + /HER2- breast cancer: insights and implications.

Journal: NPJ breast cancer

Published: March 22, 2025

Results of a patient-level pooled analysis of three studies of trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastasis.

Results of a patient-level pooled analysis of three studies of trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastasis.

Journal: ESMO open

Published: September 24, 2024

Showing 1-12 of 34

Last Updated: 09/26/2026